추천 제품
![N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxo-1-pyrrolidinyl)acetamide](/deepweb/assets/sigmaaldrich/product/structures/911/310/bc1a2cc7-fe3e-441b-9b42-6736df037fa5/640/bc1a2cc7-fe3e-441b-9b42-6736df037fa5.png)
분석
≥98% (HPLC)
양식
powder
색상
white to beige
solubility
H2O: 10 mg/mL, clear
저장 온도
2-8°C
SMILES string
[S](=O)(=O)([O-])O.[N+H](C(C)C)(C(C)C)CCNC(=O)CN1CCCC1=O
InChI
1S/C14H27N3O2.H2O4S/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19;1-5(2,3)4/h11-12H,5-10H2,1-4H3,(H,15,18);(H2,1,2,3,4)
InChI key
ACSROKXFXFNERX-UHFFFAOYSA-N
생화학적/생리학적 작용
Pramiracetam is a potent nootropic agent that is a member of the racetam drug family. Pramiracetam improves cognitive deficits associated with traumatic brain injuries. Also, pramiracetam is a specific inhibitor of prolyl endopeptidase.
Pramiracetam is a potent nootropic agent.
특징 및 장점
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
신호어
Warning
유해 및 위험 성명서
예방조치 성명서
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
Lot/Batch Number
C Mondadori et al.
Behavioural brain research, 33(1), 79-82 (1989-05-01)
The effects of the nootropic agent piracetam and its congeners oxiracetam, pramiracetam and aniracetam on the retention performance of mice in a passive-avoidance situation are dependent on the intensity of the foot-shock applied. This phenomenon is observed upon both pre-trial
L A Dziak et al.
Likars'ka sprava, (8)(8), 67-72 (2004-02-18)
Morbidity rise of cerebrovascular pathology is followed by remarkable cognitive decline. Chronic cerebral blood insufficiency and stroke consequences compose a group of the diseases which lead to different types of memory deterioration, consecutive memory decline and as a result to
T Chang et al.
Journal of clinical pharmacology, 25(4), 291-295 (1985-05-01)
The pharmacokinetics of pramiracetam, a new, investigational, cognition activator, were assessed in normal male volunteers as part of a clinical tolerance study. In a double-blind, randomized design, two groups of six subjects each received alternating placebo and single 400, 800
J J Claus et al.
Neurology, 41(4), 570-574 (1991-04-01)
The cognitive-enhancing effects of pramiracetam in animal models of learning and memory are characterized by an inverted U-shaped dose-response curve. We evaluated antidementia efficacy of this drug in 10 patients with probable Alzheimer's disease employing a 2-phase, placebo-controlled, enrichment-type trial
A J Gower et al.
Neuropharmacology, 25(10), 1161-1166 (1986-10-01)
Rats were tested for tail-flick responses and then immediately subjected to footshock for 30 sec. This procedure induced analgesia, i.e. prolonged the latency of the tail-flick response, which was maximal immediately after the shock and decayed to normal levels within
문서
신경과학을 위한 생체 활성 저분자
DISCOVER Bioactive Small Molecules for Neuroscience
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
